BERKELEY, Calif. and MAINZ, Germany, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced a 1-for-40 reverse stock split of its issued and outstanding shares. The reverse stock split was authorized by the Board of Directors of the Company pursuant to shareholder approval granted at its Extraordinary Shareholders Meeting on November 20, 2024. The reverse stock ...

Revenue increases 4% year over year while loss from operations decreases by 32% Pooled Results of ColoFuture and eAArly DETECT studies published at ASCO showing groundbreaking performance with sensitivity for CRC of 92% and 82% for advanced adenomas, including 95.8% detection of high-grade dysplasia Company highlights its path to success for 2025 BERKELEY, Calif. and MAINZ, Germany, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diag ...

Exhibit 99.2 Mainz Biomed N.V. Consolidated Statements of Financial Position (Unaudited) (Expressed in US Dollars) | | | | | December | | --- | --- | --- | --- | --- | | | | June 30, | | 31, | | | Note | 2024 | | 2023 | | ASSETS | | | | | | Current Assets | | | | | | Cash | | $ 977,764 | | $ 7,070,925 | | Trade and other receivables, net | 4 | 139,414 | | 93,555 | | Inventories | 5 | 520,531 | | 613,638 | | Prepaid expenses and other current assets | 6 | 751,994 | | 1,201,778 | | Total Current Assets | | 2, ...

BERKELEY, Calif. and MAINZ, Germany, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, today released a statement to shareholders highlighting its strategic plans for maximizing shareholder value, clinical developments, and its upcoming FDA trial anticipated for 2025, which aims to pave the way for entry into the U.S. market. Management believes 2025 will be a transformat ...

Core Insights - Mainz Biomed N.V. has appointed Petra Smeltzer Starke as a Brand Ambassador to enhance messaging on the importance of early detection of colorectal cancer [1][2] - The company plans to launch a pivotal PMA trial for its next-generation colorectal cancer screening product by the end of 2025 [2] - Mainz Biomed's flagship product, ColoAlert®, is a non-invasive diagnostic test for colorectal cancer, currently marketed in Europe and the UAE, with an ongoing pivotal FDA clinical study for US regulatory approval [6] Company Overview - Mainz Biomed specializes in molecular genetic diagnostic solutions for life-threatening conditions, focusing on early cancer detection [6] - The company is developing PancAlert, an early-stage pancreatic cancer screening test utilizing real-time PCR multiplex detection of molecular-genetic biomarkers in stool samples [6] Brand Ambassador Profile - Petra Smeltzer Starke has a distinguished background, having studied international business and law, and served in significant roles during the Obama Administration, including General Counsel to the White House Council of Economic Advisors [3][4][5] - Starke's extensive experience and international network are expected to contribute significantly to Mainz Biomed's mission in cancer detection [2][4]

BERKELEY, Calif. and MAINZ, Germany, July 25, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in early detection of cancer, today announced significant improvements to its ColoAlert product, currently being commercialized across Europe and in select international markets. These updates aim to enhance customer satisfaction and streamline lab operations. To increase screening/lab efficiency, Mainz Biomed has introduced a novel DNA stabilizing buf ...

MC Services AG Anne Hennecke/Caroline Bergmann +49 211 529252 20 mainzbiomed@mc-services.eu For investor inquiries, please contact info@mainzbiomed.com Forward-Looking Statements Certain statements made in this press release are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate", "believe", "expect", "estimate", "plan", "outlook", and "pr ...

On the basis of its positive clinical studies Mainz Biomed has now defined the final configuration including its novel mRNA biomarkers of the Next Generation Test to be used in pivotal registration study ReconAAsense A recent clinical analysis of this new configuration demonstrates sensitivity for colorectal cancer of 97% and 88% for advanced adenomas, with specificity of 93% BERKELEY, Calif. and MAINZ, Germany, July 09, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnos ...

BERKELEY, Calif. and MAINZ, Germany, July 02, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, today reviewed its major accomplishments of the first six months ending June 30, 2024, and provided a corporate update. The Company expects to release its half year financial results in September 2024. Key Highlights During First Half 2024 "I'm extremely pleased with the progress achieved during the first half of 2024 ...

BERKELEY, Calif. and MAINZ, Germany, July 02, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, today reviewed its major accomplishments of the first six months ending June 30, 2024, and provided a corporate update. The Company expects to release its half year financial results in September 2024. Key Highlights During First Half 2024 Mainz Biomed presented industry leading results of its pooled study at ASCO 2024 ...